Brenna C McDonald1, Kathleen Van Dyk2, Jeanne S Mandelblatt3, Andrew J Saykin4, Rachael L Deardorff4, Jessica N Bailey4, Wanting Zhai3, Judith E Carroll2, James C Root5, Tim A Ahles5. 1. Department of Radiology and Imaging Sciences, Indiana University School of Medicine and Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, USA. mcdonalb@iupui.edu. 2. Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine and UCLA Jonnson Comprehensive Cancer Center, University of California at Los Angeles, Los Angeles, CA, USA. 3. Georgetown University and Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA. 4. Department of Radiology and Imaging Sciences, Indiana University School of Medicine and Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, USA. 5. Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Abstract
PURPOSE: Cancer patients are concerned about treatment-related cognitive problems. We examined effects of antiestrogen hormonal therapy on brain imaging metrics in older women with breast cancer. METHODS: Women aged 60 + treated with hormonal therapy only and matched non-cancer controls (n = 29/group) completed MRI and objective and self-reported cognitive assessment at pre-treatment/enrollment and 12 months later. Gray matter was examined using voxel-based morphometry (VBM), FreeSurfer, and brain age calculations. Functional MRI (fMRI) assessed working memory-related activation. Analyses examined cross-sectional and longitudinal differences and tested associations between brain metrics, cognition, and days on hormonal therapy. RESULTS: The cancer group showed regional reductions over 12 months in frontal, temporal, and parietal gray matter on VBM, reduced FreeSurfer cortical thickness in prefrontal, parietal, and insular regions, and increased working memory-related fMRI activation in frontal, cingulate, and visual association cortex. Controls showed only reductions in fusiform gyrus on VBM and FreeSurfer temporal and parietal cortex thickness. Women with breast cancer showed higher estimated brain age and lower regional gray matter volume than controls at both time points. The cancer group showed a trend toward lower performance in attention, processing speed, and executive function at follow-up. There were no significant associations between brain imaging metrics and cognition or days on hormonal therapy. CONCLUSION: Older women with breast cancer showed brain changes in the first year of hormonal therapy. Increased brain activation during working memory processing may be a sign of functional compensation for treatment-related structural changes. This hypothesis should be tested in larger samples over longer time periods. GOV IDENTIFIER: NCT03451383.
PURPOSE: Cancer patients are concerned about treatment-related cognitive problems. We examined effects of antiestrogen hormonal therapy on brain imaging metrics in older women with breast cancer. METHODS: Women aged 60 + treated with hormonal therapy only and matched non-cancer controls (n = 29/group) completed MRI and objective and self-reported cognitive assessment at pre-treatment/enrollment and 12 months later. Gray matter was examined using voxel-based morphometry (VBM), FreeSurfer, and brain age calculations. Functional MRI (fMRI) assessed working memory-related activation. Analyses examined cross-sectional and longitudinal differences and tested associations between brain metrics, cognition, and days on hormonal therapy. RESULTS: The cancer group showed regional reductions over 12 months in frontal, temporal, and parietal gray matter on VBM, reduced FreeSurfer cortical thickness in prefrontal, parietal, and insular regions, and increased working memory-related fMRI activation in frontal, cingulate, and visual association cortex. Controls showed only reductions in fusiform gyrus on VBM and FreeSurfer temporal and parietal cortex thickness. Women with breast cancer showed higher estimated brain age and lower regional gray matter volume than controls at both time points. The cancer group showed a trend toward lower performance in attention, processing speed, and executive function at follow-up. There were no significant associations between brain imaging metrics and cognition or days on hormonal therapy. CONCLUSION: Older women with breast cancer showed brain changes in the first year of hormonal therapy. Increased brain activation during working memory processing may be a sign of functional compensation for treatment-related structural changes. This hypothesis should be tested in larger samples over longer time periods. GOV IDENTIFIER: NCT03451383.
Authors: Thomas W McAllister; Brenna C McDonald; Laura A Flashman; Richard B Ferrell; Tor D Tosteson; Norman N Yanofsky; Margaret R Grove; Andrew J Saykin Journal: Int J Psychophysiol Date: 2011-07-19 Impact factor: 2.997
Authors: Christina M Schilder; Caroline Seynaeve; Louk V Beex; Willem Boogerd; Sabine C Linn; Chad M Gundy; Hilde M Huizenga; Johan W Nortier; Cornelis J van de Velde; Frits S van Dam; Sanne B Schagen Journal: J Clin Oncol Date: 2010-02-08 Impact factor: 44.544
Authors: Florien W Boele; Christina M T Schilder; Mari-Lou de Roode; Jan Berend Deijen; Sanne B Schagen Journal: Menopause Date: 2015-01 Impact factor: 2.953
Authors: Sanne Menning; Michiel B de Ruiter; Dick J Veltman; V Koppelmans; Clemens Kirschbaum; Willem Boogerd; Liesbeth Reneman; Sanne B Schagen Journal: Neuroimage Clin Date: 2015-02-20 Impact factor: 4.881
Authors: Burcu Zeydan; Nirubol Tosakulwong; Christopher G Schwarz; Matthew L Senjem; Jeffrey L Gunter; Robert I Reid; Liliana Gazzuola Rocca; Timothy G Lesnick; Carin Y Smith; Kent R Bailey; Val J Lowe; Rosebud O Roberts; Clifford R Jack; Ronald C Petersen; Virginia M Miller; Michelle M Mielke; Walter A Rocca; Kejal Kantarci Journal: JAMA Neurol Date: 2019-01-01 Impact factor: 18.302